Voltage-gated sodium channel blockers, 2001-2006: An overview

Voltage-gated sodium channel blockers have long been used in the therapy of various central nervous system diseases, including epilepsy, chronic pain, psychiatric disorders, and spasticity. Several old agents are available with suboptimal features. Their properties may be improved by enhancing their state-dependent channel blocking action, and/or sodium channel subtype selectivity. This paper gives a short overview on the present state of research in this field, and the chemical structures of old sodium channel blockers, and those of recently published or patented compounds with sodium channel blocking action.

[1]  D. Madge,et al.  Medicinal chemistry of neuronal voltage-gated sodium channel blockers. , 2001, Journal of medicinal chemistry.

[2]  Paul B Bennett,et al.  High throughput ion-channel pharmacology: planar-array-based voltage clamp. , 2003, Assay and drug development technologies.

[3]  William A. Catterall,et al.  International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels , 2005, Pharmacological Reviews.

[4]  Balázs Gulyás,et al.  Role of sodium channel inhibition in neuroprotection: effect of vinpocetine , 2000, Brain Research Bulletin.

[5]  C. Kuo,et al.  A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. , 1998, Molecular pharmacology.

[6]  C. Kuo,et al.  Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones , 1997, British journal of pharmacology.

[7]  Jun Liang,et al.  Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain. , 2005, Bioorganic & medicinal chemistry letters.

[8]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[9]  M. Fisher,et al.  Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers. , 2006, Bioorganic & medicinal chemistry letters.

[10]  Clare,et al.  Voltage-gated sodium channels as therapeutic targets. , 2000, Drug discovery today.

[11]  P. Chazot.  Safinamide (Newron Pharmaceuticals). , 2001, Current opinion in investigational drugs.

[12]  M. Fisher,et al.  Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain. , 2005, Bioorganic & medicinal chemistry letters.

[13]  A. J. Carter,et al.  Analgesic activity of a novel use‐dependent sodium channel blocker, crobenetine, in mono‐arthritic rats , 2001, British journal of pharmacology.

[14]  H. Buschmann,et al.  Molecular diversity of voltage-gated sodium channel α and β subunit mRNAs in human tissues , 2006 .

[15]  H. Buschmann,et al.  Molecular diversity of voltage-gated sodium channel alpha and beta subunit mRNAs in human tissues. , 2006, European journal of pharmacology.

[16]  R. B. Carter,et al.  Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States , 2006, Journal of Pharmacology and Experimental Therapeutics.

[17]  J. Wood,et al.  Involvement of Na+ channels in pain pathways. , 2001, Trends in pharmacological sciences.

[18]  J. Quail,et al.  (Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. , 1996, Journal of medicinal chemistry.

[19]  Milton L. Brown,et al.  Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2. , 2006, Bioorganic & medicinal chemistry.

[20]  I. Tarnawa,et al.  Functional characterization of sodium channel blockers by membrane potential measurements in cerebellar neurons: Prediction of compound preference for the open/inactivated state , 2006, Neurochemistry International.

[21]  S. Farkas.  Silperisone: a centrally acting muscle relaxant. , 2006, CNS drug reviews.

[22]  C. Caccia,et al.  Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants. , 1999, Bioorganic & medicinal chemistry letters.

[23]  P. Pevarello,et al.  Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. , 1998, Journal of medicinal chemistry.

[24]  B. Gulyás,et al.  [11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies , 2005, Journal of the Neurological Sciences.

[25]  B. Hille,et al.  Local anesthetics: hydrophilic and hydrophobic pathways for the drug- receptor reaction , 1977, The Journal of general physiology.

[26]  J. Hunter,et al.  The role of voltage-gated sodium channels in neuropathic pain , 2003, Current Opinion in Neurobiology.

[27]  R. French,et al.  Dissecting lidocaine action: diethylamide and phenol mimic separate modes of lidocaine block of sodium channels from heart and skeletal muscle. , 1993, Biophysical journal.

[28]  R. Maj,et al.  Anti-allodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain , 2003, Pain.

[29]  H. Bölcskei,et al.  Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. , 2007, Recent patents on CNS drug discovery.

[30]  A. Gere,et al.  Tolperisone-Type Drugs Inhibit Spinal Reflexes via Blockade of Voltage-Gated Sodium and Calcium Channels , 2005, Journal of Pharmacology and Experimental Therapeutics.

[31]  R. B. Carter,et al.  V102862 (Co 102862): a potent, broad‐spectrum state‐dependent blocker of mammalian voltage‐gated sodium channels , 2005, British journal of pharmacology.